Publications by the researcher in collaboration with Maria del Carmen Asensio Lopez (37)

2025

  1. AEOL-induced NRF2 activation and DWORF overexpression mitigate myocardial I/R injury

    Molecular Medicine, Vol. 31, Núm. 1

  2. Editorial: Advanced therapeutic strategies and safety profiles in heart failure with reduced ejection fraction: contextualizing recent findings

    Frontiers in Pharmacology

2024

  1. Circulating concentrations and prognostic value of incretin hormones GLP-1 and GIP-1 in patients with heart failure.

    ESC Congress - Heart Failure 2024

  2. Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis

    European heart journal, Vol. 45, Núm. 43, pp. 4601-4615

  3. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55/YY1/sST2 signaling axis

    ESC Congress 2024

2023

  1. Circulating ST2, from biomarker to pathogenic mediator

    Revista Espanola de Cardiologia, Vol. 76, Núm. 9, pp. 672-674

  2. Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55α/YY1/sST2 signaling axis

    Molecular Therapy - Nucleic Acids, Vol. 32, pp. 704-720

2022

  1. Critical warm ischemia time point for cardiac donation after circulatory death

    American Journal of Transplantation, Vol. 22, Núm. 5, pp. 1321-1328

2021

  1. Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction

    Journal of the American College of Cardiology, Vol. 77, Núm. 14, pp. 1747-1759

  2. The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status (Scientific Reports, (2020), 10, 1, (13553), 10.1038/s41598-020-70454-8)

    Scientific Reports

  2. Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Galectina-3 as a biomarker of acute kidney injury risk in patients with decompensated heart failure

    Revista Clinica Espanola, Vol. 219, Núm. 6, pp. 315-319

  2. Temporal characterization of cardiac expression of glucose transporters SGLT and GLUT in an experimental model of myocardial infarction

    Diabetes and Metabolism

  3. The Interleukin-1 Axis and Risk of Death in Patients With Acutely Decompensated Heart Failure

    Journal of the American College of Cardiology, Vol. 73, Núm. 9, pp. 1016-1025

  4. Yin-Yang 1 transcription factor modulates ST2 expression during adverse cardiac remodeling post-myocardial infarction

    Journal of Molecular and Cellular Cardiology, Vol. 130, pp. 216-233

2018

  1. Noncardiac Production of Soluble ST2 in ST-Segment Elevation Myocardial Infarction

    Journal of the American College of Cardiology

  2. Pharmacological inhibition of the mitochondrial NADPH oxidase 4/PKCα/Gal-3 pathway reduces left ventricular fibrosis following myocardial infarction

    Translational Research, Vol. 199, pp. 4-23

  3. Pulmonary Production of Soluble ST2 in Heart Failure

    Circulation. Heart failure, Vol. 11, Núm. 12, pp. e005488

  4. Short-term Serial Measurement of Galectin-3 in Hospitalized Patients With Acute Heart Failure

    Revista Espanola de Cardiologia, Vol. 71, Núm. 5, pp. 401-402